China Biologic Products Holdings Inc (NASDAQ:CBPO) has earned a consensus recommendation of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $78.00.

A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Gerdau from a “sell” rating to a “hold” rating in a report on Monday, May 13th. ValuEngine downgraded Zuora from a “buy” rating to a “hold” rating in a report on Saturday, June 1st. Finally, BidaskClub downgraded Weyco Group from a “sell” rating to a “strong sell” rating in a report on Saturday, July 13th.

Shares of CBPO traded up $0.24 during trading hours on Monday, reaching $93.24. The company’s stock had a trading volume of 83,700 shares, compared to its average volume of 198,529. The company has a market cap of $3.66 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 4.81 and a beta of 1.25. China Biologic Products has a 1-year low of $60.08 and a 1-year high of $105.50. The firm has a 50 day moving average of $93.31.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. China Biologic Products had a return on equity of 8.81% and a net margin of 27.71%. The company had revenue of $129.78 million for the quarter, compared to the consensus estimate of $119.50 million. During the same quarter in the prior year, the company earned $1.21 EPS. On average, research analysts predict that China Biologic Products will post 3.87 EPS for the current year.

Institutional investors have recently made changes to their positions in the business. Parametrica Management Ltd bought a new stake in China Biologic Products during the first quarter worth approximately $334,000. Greenwoods Asset Management Ltd boosted its position in China Biologic Products by 281.8% during the first quarter. Greenwoods Asset Management Ltd now owns 479,580 shares of the biopharmaceutical company’s stock worth $43,762,000 after purchasing an additional 353,980 shares during the period. FMR LLC boosted its position in China Biologic Products by 64.6% during the fourth quarter. FMR LLC now owns 737,579 shares of the biopharmaceutical company’s stock worth $55,990,000 after purchasing an additional 289,485 shares during the period. D. E. Shaw & Co. Inc. boosted its position in China Biologic Products by 27.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 127,660 shares of the biopharmaceutical company’s stock worth $9,691,000 after purchasing an additional 27,213 shares during the period. Finally, Laurion Capital Management LP bought a new stake in China Biologic Products during the first quarter worth approximately $317,000. 35.27% of the stock is owned by hedge funds and other institutional investors.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Read More: What is a closed-end mutual fund (CEF)?

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.